Inclusion criteria | Exclusion criteria |
---|---|
Diagnosis of T2DM with insulin therapy for at least 3 months and an HbA1c of ≥7%; negative islet cell autoantibody testing will be required for patients that received insulin therapy within 1 year after T2DM diagnosis | Type I diabetes mellitus or latent autoimmune diabetes of adults (LADA) |
Proof of at least one microvascular manifestation of diabetes (for example, nephropathy, retinopathy, neuropathy) | T2DM on diet and/or oral medication |
Residual pancreatic function, which is the premise for autogenic glycemic control assessed by stimulated fasting C-peptide laboratory tests with a minimum of 1.5 ng/mL | Heart failure (NYHA III-IV) |
Pregnancy | |
BMI 26–35 kg/m2 | Malignant disease in the past 5 years |
Age 30 to 65 years | History of major abdominal operation |
Permanent glucocorticoid or other immunosuppressive therapy | |
Pituitary disease/Morbus Addison | |
Renal failure (glomerular filtration rate < 45 ml/min) | |
Proof of any liver cirrhosis above grade A according to the Child-Pugh-classification | |
Expected lack of compliance or inability to informed consent |